SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) September 14, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that
clinical investigators at the Joslin Diabetes Center in
Boston, Massachusetts will coordinate and conduct a
clinical trial to satisfy requirements of Biocontrol's
premarket approval (PMA) submission to the U.S. Food
and Drug Administration (FDA) for the Company's
Diasensor 2000 Noninvasive Glucose Monitor. The trial
will evaluate the Diasensor 2000 and its use in a new
telemedicine program that wraps the monitor into an
overall diabetes care program in which the patient
using the Diasensor in the home will be linked via the
internet to a specialty diabetes clinic.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: September 14, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
JOSLIN DIABETES CENTER TO CONDUCT CLINICAL TRIAL FOR
BIOCONTROL'S DIASENSOR 2000 FDA SUBMISSION
Pittsburgh, PA - September 14, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today that clinical investigators at
the Joslin Diabetes Center in Boston, Massachusetts will
coordinate and conduct a clinical trial to satisfy requirements
of Biocontrol's premarket approval (PMA) submission to the U.S.
Food and Drug Administration (FDA) for the Company's Diasensor
2000 Noninvasive Glucose Monitor. The trial will be conducted in
accordance with a contract encompassing a protocol written by the
Joslin Diabetes Center.
The trial will evaluate the Diasensor 2000 and its use in a
new telemedicine program that wraps the monitor into an overall
diabetes care program in which the patient using the Diasensor in
the home will be linked via the internet to a specialty diabetes
clinic. Further details of the study, which is expected to begin
within a few months, will be released when approved by all
parties.
Joslin Diabetes Center is an international leader in
diabetes treatment, research, and education. Established in
1898, and affiliated with Harvard Medical School, Joslin leads
the field in both basic and clinical research, and is devoted to
educating both patients and professionals. Joslin is
headquartered in Boston and has facilities throughout
Massachusetts, as well as affiliated diabetes treatment centers
throughout the U.S. from New York City to Florida. Further
information on Joslin Diabetes Center can be found at
www.joslin.org.
Biocontrol began the modular PMA process with submission of
its first module to the FDA in May of this year. Biocontrol
President, David L. Purdy, said, "Biocontrol is pleased to work
with the Joslin Diabetes Center whose integrity and reputation
will certainly ensure a sound clinical trial of the Diasensor
2000 and the new telemedicine in-home health care program for
people with diabetes."
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Subsidiary,
Diasensor.com, Inc., also located in Pittsburgh, PA owns the
patents, marketing and distribution rights to the sensor while
Biocontrol has the exclusive rights to the research and
development and manufacturing of the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
